Oncolytics After 2017 Refresh: New CEO Makes New Year Resolutions
2018 will be a year of change for Calgary, Canada-based Oncolytics Biotech, according to its CEO Dr. Matt Coffey. After switching gears to focus on metastatic breast cancer as the lead indication for its oncolytic virus-based drug candidate Reolysin, the biotech is ready to enter Phase III and step-up its clinical and commercial activities.
You may also be interested in...
AstraZeneca inks a deal with French firm Transgene to co-develop five armed oncolytic vaccinia virus candidates in an area that is hotting up for big pharma.
The Scrip 100 universe gathers FY2021 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales.
A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series.